Resolution of symptoms · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at longest · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events during the study period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes serious adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
Adverse events during treatment period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes any adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
Suicide or suicide attempt (at longest · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed symptomatic COVID‐19b
1 finding from 1 review
Systemic reactogenicity events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Local reactogenicity events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe or critical COVID‐19
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Confirmed symptomatic COVID‐19b
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe or critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortalityb
It is very uncertain whether booster changes all‐cause mortalityb compared with placebo/no booster (very low certainty).
1 finding from 1 review
Systemic reactogenicity events
Booster showed no clear difference in systemic reactogenicity eventsf compared with placebo/no booster (low certainty).
1 finding from 1 review
Any adverse event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Local reactogenicity events
Booster probably leads to higher local reactogenicity eventsf compared with placebo/no booster (moderate certainty).
1 finding from 1 review